Aspen offers excessive-pricing commitments

Aspen has said it will reduce its prices for six cancer drugs in Europe by an average of 73%, as part of a commitment package seeking to end the EU antitrust watchdog’s first excessive-pricing investigation in the pharmaceutical sector.


Get unlimited access to all Global Competition Review content